Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TALAZOPARIB for Prostate cancer: Side Effects & Safety Data

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

There are 125 adverse event reports in the FDA FAERS database where TALAZOPARIB was used for Prostate cancer.

Most Reported Side Effects for TALAZOPARIB

Side Effect Reports % Deaths Hosp.
Anaemia 219 14.8% 20 80
Neoplasm progression 169 11.4% 54 37
Death 142 9.6% 142 9
Off label use 78 5.3% 16 13
Thrombocytopenia 78 5.3% 17 33
Fatigue 77 5.2% 5 17
Platelet count decreased 68 4.6% 8 30
Haemoglobin decreased 65 4.4% 1 24
Febrile neutropenia 60 4.1% 9 52
Pancytopenia 60 4.1% 7 24
Nausea 53 3.6% 3 17
Neutropenia 47 3.2% 3 13
Dyspnoea 43 2.9% 12 29
Asthenia 39 2.6% 3 16
Haematotoxicity 38 2.6% 1 5

Other Indications for TALAZOPARIB

Prostate cancer metastatic (155) Breast cancer metastatic (146) Breast cancer (119) Breast cancer female (69) Hormone-refractory prostate cancer (69) Product used for unknown indication (61) Neoplasm (29) Triple negative breast cancer (26) Neoplasm malignant (18) Ovarian cancer (18)

Other Drugs Used for Prostate cancer

LEUPROLIDE (45,399) ENZALUTAMIDE (25,954) RELUGOLIX (18,752) ABIRATERONE (12,209) APALUTAMIDE (3,286) GOSERELIN (2,080) DEGARELIX (2,035) BICALUTAMIDE (1,832) SIPULEUCEL-T (1,720) DENOSUMAB (1,627)

Related Pages

TALAZOPARIB Full Profile All Prostate cancer Drugs TALAZOPARIB Demographics TALAZOPARIB Timeline